drugset
Drugs / hLL1-DOX
last change Oct 2017 re-read 3 minutes ago

hLL1-DOX

Developed for
chronic lymphocytic leukemia/small lymphocytic lymphoma · plasma cell myeloma
Investigated by
Gilead Sciences

Trials 2

today NCT01585688 · Ph 1/2 NCT01101594 · Ph 1/2
20112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT01585688 Aug 2012 → Nov 2016 chronic lymphocytic leukemia/small lymphocytic lymphoma Gilead Sciences Terminated No outcome recorded
Phase 1/2 NCT01101594 Jul 2010 → Jul 2013 plasma cell myeloma Gilead Sciences Terminated No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as hLL1-DOX ClinicalTrials.gov intervention name — accepted as the source's own label NCT01101594 ↗
1

NCT01585688 ↗
Route Intravenous “hLL1-DOX will be administered intravenously (through a vein)” NCT01101594 ↗